Ann: TACTI-002 & INSIGHT-004 data to be presented at ASCO, page-45

G'day Ahjay and all Immutep 'Lag(3)gards',

Yervov - CTLA-4 is thought to regulate T-cell proliferation early in an immune response, primarily in lymph nodes, whereas PD-1 suppresses T cells later in an immune response, primarily in peripheral tissues.

Opdivo - PD-1 (Nivolumab) is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.

Efti - LAG-3 - MHC class II agonist eftilagimod alpha (efti, IMP321 or LAG-3Ig) is a soluble LAG-3 protein that activates APC leading to CD8 T-cell activation.

LAG-3 and PD-1 have synergistic benefits. 'Pressing the gas and releasing the brakes' analogy.

Although programmed death-ligand 1 (PD-L1) antibody–based therapy has improved the outcome of patients with
cancer, acquired resistance to these treatments limits their clinical efficacy. LAG-3 and PD-L1 with the potential to reinvigorate exhausted immune cells and overcome resistance mechanisms to PD-L1 blockade.

Therefore reason efti combo patent application not registered with Yervoy (or any CTLA-4 compound)